Evolent Health (EVH) Set to Announce Quarterly Earnings on Thursday

Posted by Stanley Muller on Oct 29th, 2026

Evolent Health (NYSE:EVH – Get Free Report) is expected to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Evolent Health to post earnings of $0.06 per share and revenue of $727.06 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Evolent Health (NYSE:EVH – Get Free Report) last posted its earnings results on Thursday, August 6th. The technology company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.03. The company had revenue of $484.50 million for the quarter, compared to analyst estimates of $597.70 million. Evolent Health had a negative return on equity of 4.27% and a negative net margin of 24.08%. The company’s revenue for the quarter was up 46.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.10) earnings per share. On average, analysts expect Evolent Health to post ($0.25) EPS for the current fiscal year and ($0.04) EPS for the next fiscal year.

Evolent Health Stock Down 2.1%

Shares of NYSE:EVH opened at $4.33 on Thursday. The business’s 50 day moving average is $4.20 and its 200 day moving average is $3.87. Evolent Health has a 12-month low of $2.10 and a 12-month high of $7.50. The stock has a market cap of $488.98 million, a price-to-earnings ratio of -0.95 and a beta of 1.02. The company has a quick ratio of 1.24, a current ratio of 1.24 and a debt-to-equity ratio of 2.52.

Analyst Ratings Changes

Several equities analysts have weighed in on EVH shares. Truist Financial dropped their price objective on Evolent Health from $7.00 to $6.00 and set a “hold” rating on the stock in a research note on Wednesday, August 12th. Citigroup raised shares of Evolent Health from a “neutral” rating to a “buy” rating and cut their price objective for the stock from $6.75 to $6.00 in a report on Monday, August 10th. Weiss Ratings lowered shares of Evolent Health from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 16th. Canaccord Genuity Group reduced their target price on shares of Evolent Health from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Monday, August 10th. Finally, TD Cowen increased their target price on shares of Evolent Health from $5.00 to $6.00 and gave the company a “buy” rating in a report on Monday, August 17th. Eleven equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $5.96.

Check Out Our Latest Stock Analysis on EVH

Insider Buying and Selling at Evolent Health

In other news, President Daniel Mccarthy sold 65,892 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $5.00, for a total value of $329,460.00. Following the transaction, the president owned 655,133 shares in the company, valued at $3,275,665. The trade was a 9.14% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.48% of the stock is owned by insiders.

Evolent Health Company Profile

(Get Free Report)

Evolent Health, Inc (NYSE: EVH) is a healthcare services and technology company that helps health plans and healthcare providers transition to value-based care. Its platform is designed to support the management of clinical programs, improve patient outcomes and coordinate care while helping customers manage healthcare costs.

The company provides specialty and total-cost-of-care solutions across areas such as cardiology, oncology, musculoskeletal care, radiology and other complex conditions.